Options
In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018–2020
Journal
Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi
Date Issued
2021-09-04
Author(s)
Liu, Po-Yu
Ko, Wen-Chien
Lee, Wen-Sen
Lu, Po-Liang
Chen, Yen-Hsu
Cheng, Shu-Hsing
Lu, Min-Chi
Lin, Chi-Ying
Wu, Ting-Shu
Yen, Muh-Yong
Wang, Lih-Shinn
Liu, Chang-Pan
Lee, Yu-Lin
Shi, Zhi-Yuan
Chen, Yao-Shen
Wang, Fu-Der
Tseng, Shu-Hui
Lin, Chao-Nan
Chen, Yu-Hui
Lee, Chun-Ming
Tang, Hung-Jen
Abstract
This study aimed to investigate the in vitro susceptibilities of carbapenem-non-susceptible Pseudomonas aeruginosa (CNSPA) and Acinetobacter baumannii (CNSAB) isolates to cefiderocol, novel β-lactamase inhibitor (BLI) combinations, new tetracycline analogues, and other comparative antibiotics.
Subjects
Cefepime/enmetazobactam; Cefepime/zidebactam; Cefiderocol; Eravacycline; Omadacycline
Type
journal article